ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08945
-0,01%
Bitcoin
66.856,09
-0,33%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Crinetics Pharmaceuticals Inc (CRNX)

  7. Crinetics Pharmaceuticals Inc (CRNX) News

CRNX

Crinetics Pharmaceuticals (CRNX)

Crinetics Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:CRNX
DatumZeitQuelleÜberschriftSymbolFirma
15/05/202400h29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRNXCrinetics Pharmaceuticals Inc
10/05/202422h57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRNXCrinetics Pharmaceuticals Inc
10/05/202418h40Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CRNXCrinetics Pharmaceuticals Inc
09/05/202422h38Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CRNXCrinetics Pharmaceuticals Inc
09/05/202422h12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRNXCrinetics Pharmaceuticals Inc
08/05/202423h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRNXCrinetics Pharmaceuticals Inc
08/05/202422h19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CRNXCrinetics Pharmaceuticals Inc
11/03/202421h15Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:CRNXCrinetics Pharmaceuticals Inc
07/03/202402h18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRNXCrinetics Pharmaceuticals Inc
07/03/202402h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRNXCrinetics Pharmaceuticals Inc
07/03/202402h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRNXCrinetics Pharmaceuticals Inc
07/03/202402h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRNXCrinetics Pharmaceuticals Inc
07/03/202401h59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRNXCrinetics Pharmaceuticals Inc
07/03/202401h57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRNXCrinetics Pharmaceuticals Inc
01/03/202422h41Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:CRNXCrinetics Pharmaceuticals Inc
28/02/202422h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRNXCrinetics Pharmaceuticals Inc
14/02/202422h28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRNXCrinetics Pharmaceuticals Inc
12/02/202422h32Edgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:CRNXCrinetics Pharmaceuticals Inc
26/01/202423h50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRNXCrinetics Pharmaceuticals Inc
25/01/202419h03Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CRNXCrinetics Pharmaceuticals Inc
12/01/202422h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRNXCrinetics Pharmaceuticals Inc
10/01/202418h10Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CRNXCrinetics Pharmaceuticals Inc
08/01/202414h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRNXCrinetics Pharmaceuticals Inc
04/01/202422h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRNXCrinetics Pharmaceuticals Inc
04/01/202422h43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRNXCrinetics Pharmaceuticals Inc
03/01/202422h11Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CRNXCrinetics Pharmaceuticals Inc
02/01/202422h44Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CRNXCrinetics Pharmaceuticals Inc
27/12/202323h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRNXCrinetics Pharmaceuticals Inc
26/12/202317h47Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CRNXCrinetics Pharmaceuticals Inc
23/12/202300h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRNXCrinetics Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:CRNX

Kürzlich von Ihnen besucht

USOTC
LCCTF
L Occitane (PK)
BIT
F17331
Vontobel Financial Produ...
NASDAQ
FCOVGX
FTP Innovative Health Ca...
BIT
UB5U2L
Unicredit Bank
EU
W996S
W996S
COIN
DUCBTC
COIN
BPSEUR
LSE
64TR
Asb Bk. 29
USOTC
EFRGF
Pasofino Gold (QB)
GATE
GALUSDT
Galatasaray S.K.
COIN
SPRKRGBP
LSE
1ARG
Ark Genomic 1x
BSTP
UNIEUR
Uniswap
LSE
SM33
Citi Fun 24
COIN
BTCRUBTC
NYSE
NEE-I
NextEra Energy
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten